🧠Oruen CNS Weekly Roundup: The Latest in CNS Medicine 🧠Â
The CNS field continues to evolve rapidly, with new developments emerging across psychiatry, neurology, and interventional neuroscience. This week’s roundup highlights key updates across multiple therapeutic areas.
Depression
Single-Day GH001 Produces Rapid Remission in TRD
HCPLive’s March 31 piece highlights phase 2b data for inhaled GH001 in treatment-resistant depression. In the randomized trial, a single-day individualized dosing session was associated with a large day-8 MADRS benefit versus placebo, with remission reported in 57.5% of treated patients and 0% of placebo patients. It is one of the more notable rapid-acting psychiatry stories of the week because it combines fast onset with a lower-visit treatment model. Source: https://www.hcplive.com/view/single-day-gh001-produces-rapid-remission-trd-michael-e-thase-md
Alzheimer’s disease
Blood protein structure changes may enable earlier detection of Alzheimer’s
This News-Medical report covers a Nature Aging study using structural proteomics plus machine learning to classify Alzheimer’s disease and separate it from mild cognitive impairment using blood-based protein signatures. The appeal here is not just earlier detection, but the possibility of a more scalable, minimally invasive biomarker strategy. Source: https://www.news-medical.net/news/20260313/Blood-protein-structure-changes-may-enable-earlier-detection-of-Alzheimere28099s.aspx
Headache / Migraine
GLP-1 Liraglutide Displays Effectiveness as Migraine Treatment in Early-Stage Study
NeurologyLive reports early pilot data suggesting liraglutide reduced mean monthly headache days from 19.8 to 10.7 in obese patients with chronic or high-frequency migraine who had not responded to at least two preventive treatments. The article frames this as part of a broader shift toward targeting intracranial pressure biology in selected migraine populations. Source: https://www.neurologylive.com/view/glp-1-liraglutide-displays-effectiveness-migraine-treatment-early-stage-study
Movement disorders
EJS ACT-PD Platform Trial to Test Multiple Potential Disease-Modifying Treatments for Parkinson Disease
This NeurologyLive article covers a new UK phase 3 platform trial designed to test multiple Parkinson’s candidates against a shared placebo, with plans to recruit 1,600 participants across more than 40 sites. The main reason it stands out is the platform-trial design: it is meant to accelerate disease-modifying research while widening access through virtual visits and broader infrastructure. Source: https://www.neurologylive.com/view/ejs-act-pd-platform-trial-test-multiple-potential-disease-modifying-treatments-parkinsons
Stroke
Expanding Stroke AI: How Net Water Uptake May Refine Thrombectomy and Transfer Decisions
NeurologyLive’s coverage from ISC 2026 focuses on automated net water uptake analysis from standard non-contrast CT. The clinical angle is important: if validated in practice, this could improve edema assessment, support thrombectomy selection, and help standardize transfer decisions in hospitals that do not have advanced perfusion imaging. Source: https://www.neurologylive.com/view/expanding-stroke-ai-how-net-water-uptake-may-refine-thrombectomy-transfer-decisions
Neuro-oncology
Mayo Clinic researchers develop experimental nanotherapy to treat aggressive brain tumors
News-Medical summarizes Mayo Clinic work on a nanotherapy that packages two existing cancer drugs into particles engineered to cross the blood-brain barrier and target glioblastoma. In preclinical models using patient-derived tissue, combining the approach with radiation reportedly more than doubled survival versus untreated controls, making this a credible translational neuro-oncology item rather than a purely conceptual lab finding. Source: https://www.news-medical.net/news/20260406/Mayo-Clinic-researchers-develop-experimental-nanotherapy-to-treat-aggressive-brain-tumors.aspx
Pain
Pain neurons protect nerve health and offer new therapeutic targets
Medical Xpress reports on work identifying RNase4 as a molecule produced by pain-sensing neurons that appears to help maintain nerve integrity and influence nearby myelinated fibers. The finding matters because it reframes nociceptors as active regulators of nerve health, not just passive detectors of painful stimuli, which could open up new pain-treatment strategies. Source: https://medicalxpress.com/news/2026-03-pain-neurons-nerve-health-therapeutic.html
Psychosis / Schizophrenia
Cheek cells may provide clues to schizophrenia risk
This Medical Xpress article covers research suggesting buccal-cell markers, including Sp4 mRNA expression and HSP60, may correlate with cognitive deficits in schizophrenia. The reason to watch it is practical: cheek-swab biomarkers would be far easier to scale than invasive CNS sampling, though this remains an early-stage biomarker story rather than a near-term clinical test. Source: https://medicalxpress.com/news/2026-03-cheek-cells-clues-schizophrenia.htmlÂ